Archives

Lower research and development expenses helped Chemokine Therapeutics Corp. (TSX:CTI) cut company losses to $6.2 million in 2007 compared with losses of $7.5 million in 2006. The Vancouver company had no revenue in either year.

Hanwei Energy Services Corp. (TSX:HE), one of China's largest manufacturers of fibreglass-reinforced plastic pipes for the oil and gas sector, is forecasting even stronger growth of more than 70% this year after a record-breaking 2007.

Vancouver's Emri Group Ltd. has invested $37 million acquiring two commercial properties in southern California. The real estate investment firm bought the properties for what it believes are below current market and replacement prices.

Lululemon Athletica Inc. (NASDAQ:LULU, TSX:LLL) has reported a net income of $30.8 million for 2007 compared with $7.7 million for 2006. The Vancouver yoga-wear retailer said its revenue rose 84% in 2007 to $274.7 million from $148.9 million in 2006.

Tranzeo Wireless Technologies Inc. (TSX:TZT) has reported that it has secured a contract to provide wireless Internet access for the entire city of Culiacan, Mexico.

PMC-Sierra (Nasdaq:PMCS) has appointed Greg Lang as its new president and CEO. The broadband technology developer said the appointment will be effective immediately following the resignation of Robert Bailey, the company's current president and CEO.

Vancouver-based Polaris Minerals Corp. (TSX:PLS) rolled up an $18.4 million loss in 2007. That's roughly six times the company's fiscal 2006 loss of $3.3 million. Polaris said the red ink amounted to $0.52 per share compared with $0.

Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI; NASDAQ:FMTID) reported a 31% increase in revenue for 2007 compared with 2006, but the Vancouver life sciences company also incurred a net loss of $11.6 million. Its 2007 operating loss amounted to $0.

Ascalade Communications Inc. (TSX:ACG) reported that it won't be able to provide its shareholders with its fiscal 2007 financial statements because of its Companies' Creditors Arrangement Act (CCAA) application.

Tekmira Pharmaceuticals (TSX:TKM) has bought privately owned Protiva Biotherapeutics in a new agreement aimed at ending the dispute between the companies over the rights to their drug delivery technology.